Araris Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 23

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.14B

  • Investors
  • 1

Araris General Information

Description

Developer of an antibody-drug conjugate linker technology designed to pioneer targeted cancer therapies. The company offers a proprietary peptide linker platform and enzymatic conjugation tools, enabling pharmaceutical partners to attach payloads to off-the-shelf antibodies in a single step to create homogeneous and stable therapeutics for the treatment of non-Hodgkin lymphoma and other malignancies.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Riedhofstrasse 11
  • Au
  • 8804 Zurich
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Riedhofstrasse 11
  • Au
  • 8804 Zurich
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Araris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 31-Mar-2025 $1.14B Completed Generating Revenue
9. Accelerator/Incubator 05-May-2023 Completed Generating Revenue
8. Early Stage VC 11-Apr-2023 Completed Generating Revenue
7. Early Stage VC (Series A) 04-Oct-2022 Completed Generating Revenue
6. Early Stage VC 22-Oct-2020 Completed Generating Revenue
5. Early Stage VC (Series A) 27-Jun-2019 Cancelled Startup
4. Accelerator/Incubator 27-Jun-2019 Completed Startup
3. Accelerator/Incubator Completed Startup
2. University Spin-Out 01-Jan-2019 Completed Startup
1. Grant 03-Oct-2018 $20.6K Completed Startup
To view Araris’s complete valuation and funding history, request access »

Araris Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
To view Araris’s complete cap table history, request access »

Araris Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an antibody-drug conjugate linker technology designed to pioneer targeted cancer therapies. The company off
Drug Discovery
Zurich, Switzerland
23 As of 2026

London, United Kingdom
 

Danvers, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Araris Competitors (59)

One of Araris’s 59 competitors is Akari Therapeutics, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akari Therapeutics Formerly VC-backed London, United Kingdom
Cell Signaling Technology Corporation Danvers, MA
Cytovance Biologics Formerly PE-Backed Oklahoma City, OK
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Byondis Corporation Nijmegen, Netherlands
You’re viewing 5 of 59 competitors. Get the full list »

Araris Patents

Araris Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026215442-A1 Antibody-drug conjugates comprising multiple payloads Pending 09-Apr-2025
US-20260014265-A1 Triple-payload antibody-drug conjugates (adcs) Pending 10-Jul-2024
WO-2026013234-A1 Triple-payload antibody-drug conjugates (adcs) Pending 10-Jul-2024
AU-2024364674-A1 Antibody-drug conjugates using two different types of topoisomerase i inhibitors Pending 15-Oct-2023
EP-4731265-A1 Antibody-drug conjugates using two different types of topoisomerase i inhibitors Pending 15-Oct-2023 A61K47/68037
To view Araris’s complete patent history, request access »

Araris Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Araris Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
4BIO Capital Venture Capital Minority
ETH Zurich University
Innosuisse Government
Institute for Follicular Lymphoma Innovation Not-For-Profit Venture Capital Minority
Kinled Holding Family Office Minority
You’re viewing 5 of 14 investors. Get the full list »

Araris Investments (2)

Araris’s most recent deal was a Corporate Asset Purchase with Innate Pharma (Portfolio of Transglutaminase Patents in Marseille, France). The deal was made on 24-Sep-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Innate Pharma (Portfolio of Transglutaminase Patents in Marseille, France) 24-Sep-2024 Corporate Asset Purchase Buildings and Property
ARS Pharmaceuticals (Nectin-4 Antibody) 17-Apr-2023 Corporate Asset Purchase Buildings and Property
To view Araris’s complete investments history, request access »

Araris FAQs

  • When was Araris founded?

    Araris was founded in 2018.

  • Where is Araris headquartered?

    Araris is headquartered in Zurich, Switzerland.

  • What is the size of Araris?

    Araris has 23 total employees.

  • What industry is Araris in?

    Araris’s primary industry is Drug Discovery.

  • Is Araris a private or public company?

    Araris is a Private company.

  • What is the current valuation of Araris?

    The current valuation of Araris is .

  • What is Araris’s current revenue?

    The current revenue for Araris is .

  • How much funding has Araris raised over time?

    Araris has raised $43.5M.

  • Who are Araris’s investors?

    4BIO Capital, ETH Zurich, Innosuisse, Institute for Follicular Lymphoma Innovation, and Kinled Holding are 5 of 14 investors who have invested in Araris.

  • Who are Araris’s competitors?

    Akari Therapeutics, Cell Signaling Technology, Cytovance Biologics, CytomX Therapeutics, and Byondis are some of the 59 competitors of Araris.

  • When was Araris acquired?

    Araris was acquired on 31-Mar-2025.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process